HDAC inhibitors, as well as proteasome inhibitors, sensitize HCC cells to TRAIL induced apoptosis mainly through the downregulation of cFLIP proteins without significant effects on primary human hepatocytes, showing a tumor cell-specific synergy [93,94]. This evidence concerns the gene HDAC9 and hepatocellular carcinoma.